- Evofem Biosciences Announces Financial Results for the First Quarter of 2024
- Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
- Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
- Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
- For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
More ▼
Key statistics
On Friday, Evofem Biosciences Inc (EVFM:QBB) closed at 0.0145, 45.00% above the 52 week low of 0.01 set on May 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.019 |
---|---|
High | 0.019 |
Low | 0.0139 |
Bid | -- |
Offer | -- |
Previous close | 0.0174 |
Average volume | 1.60m |
---|---|
Shares outstanding | 62.06m |
Free float | 62.06m |
P/E (TTM) | 0.0015 |
Market cap | 899.88k USD |
EPS (TTM) | -5.92 USD |
Data delayed at least 15 minutes, as of May 17 2024 20:59 BST.
More ▼